These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25496150)

  • 41. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists.
    Clegg JP; Guest JF; Lehman A; Smith AF
    Ophthalmic Epidemiol; 2006 Aug; 13(4):263-74. PubMed ID: 16877285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Establishing and sustaining a biorepository network in Israel: challenges and progress.
    Cohen Y; Almog R; Onn A; Itzhaki-Alfia A; Meir K
    Biopreserv Biobank; 2013 Dec; 11(6):331-8. PubMed ID: 24835362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A contribution for cost models in biobanking.
    Huttin C; Stubbs A
    Technol Health Care; 2016; 24(1):93-8. PubMed ID: 26757438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Funding sources for Canadian biorepositories: the role of user fees and strategies to help fill the gap.
    Barnes RO; Schacter B; Kodeeswaran S; ; Watson PH
    Biopreserv Biobank; 2014 Oct; 12(5):300-5. PubMed ID: 25314324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.
    Kanavos P; Ferrario A; Vandoros S; Anderson GF
    Health Aff (Millwood); 2013 Apr; 32(4):753-61. PubMed ID: 23569056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Traditional and electronic informed consent for biobanking: a survey of U.S. biobanks.
    Simon CM; Klein DW; Schartz HA
    Biopreserv Biobank; 2014 Dec; 12(6):423-9. PubMed ID: 25496155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next Chapter of the Taiwan Biobank: Sustainability and Perspectives.
    Lin JC; Chen LK; Hsiao WW; Fan CT; Ko ML
    Biopreserv Biobank; 2019 Apr; 17(2):189-197. PubMed ID: 30715914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Financial stability in biobanking: unique challenges for disease-focused foundations and patient advocacy organizations.
    Bromley RL
    Biopreserv Biobank; 2014 Oct; 12(5):294-9. PubMed ID: 25313427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effective organization of an institutional human cancer biobank in a clinical setting: CRO-Biobank experience toward harmonization.
    Cervo S; De Paoli P; Perin T; Canzonieri V; Steffan A
    Int J Biol Markers; 2015 May; 30(2):e243-51. PubMed ID: 25744364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. International comparison of drug consumption: impact of prices.
    Szuba TJ
    Soc Sci Med; 1986; 22(10):1019-25. PubMed ID: 3090706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biobank Continuity Management: A Survey of Biobank Professionals.
    Church TD; Richmond FJ
    Biopreserv Biobank; 2019 Oct; 17(5):410-417. PubMed ID: 31017454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biobank Report: United Kingdom.
    Kaye J; Bell J; Briceno L; Mitchell C
    J Law Med Ethics; 2016 Mar; 44(1):96-105. PubMed ID: 27256127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Embryo donation in developing countries].
    Alvarez-Díaz JA
    Gac Med Mex; 2010; 146(3):228-41. PubMed ID: 20957822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The challenge of sustaining a hospital-based biobank and core molecular laboratory: the Beaumont experience.
    Wilson GD; D'Angelo K; Pruetz BL; Geddes TJ; Larson DM; Akervall J
    Biopreserv Biobank; 2014 Oct; 12(5):306-11. PubMed ID: 25314610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 'Access arrangements' for biobanks: a fine line between facilitating and hindering collaboration.
    Fortin S; Pathmasiri S; Grintuch R; Deschênes M
    Public Health Genomics; 2011; 14(2):104-14. PubMed ID: 20689244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the financial, operational, and social sustainability of a biobank: the Wales Cancer Bank case study.
    Parry-Jones A
    Biopreserv Biobank; 2014 Dec; 12(6):381-8. PubMed ID: 25496149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drivers and constraints to environmental sustainability in UK-based biobanking: balancing resource efficiency and future value.
    Samuel G; Sims JM
    BMC Med Ethics; 2023 Jun; 24(1):36. PubMed ID: 37264320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biobank Quality Management in the BBMRI.be Network.
    Linsen L; T'Joen V; Van Der Straeten C; Van Landuyt K; Marbaix E; Bekaert S; Ectors N
    Front Med (Lausanne); 2019; 6():141. PubMed ID: 31294024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health care policy and abortion: a comparison.
    Cohen SS
    Nurs Outlook; 1990; 38(1):20-5. PubMed ID: 2403668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Finding the Path to Biobank Sustainability Through Sound Business Planning.
    Henderson M; Simeon-Dubach D; Albert M
    Biopreserv Biobank; 2015 Dec; 13(6):385-6. PubMed ID: 26697906
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.